Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products and other therapies. Co.'s diabetes products include: Basaglar®, a long-acting human insulin analog for the treatment of diabetes; and Trajenta®, for the treatment of type 2 diabetes. Co.'s oncology products include: Alimta®, for treatment of patients with non-squamous cell histology and no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations. When considering the Lilly (Eli) & Co stock dividend history, we have taken known splits into account, such that the LLY dividend history is presented on a split-adjusted ("apples to apples") basis. Lilly (Eli) & Co dividend history is presented both in graphical/chart form, and as a LLY dividend history data table along the right-hand column.
|
LLY Stock Dividend HistoryThe LLY dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable LLY historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the LLY dividend history record. Also see the LLY stock dividend history data table along the right-hand column below. |
|
LLY Next Dividend Date » (Projection based upon history) LLY Dividend Growth Rate » Quotes delayed 20 minutes |
Strong Buy (3.79 out of 4) 73rd percentile
(ranked higher than approx. 73% of all stocks covered)
Analysts' Target Price: LLY Forecast Based on data provided by Zacks Investment Research via Quandl.com |
Projection: LLY Next Dividend Date Chart: LLY Chart - 5Yr Dividend Yield |